Tarsons Q1 FY27 Revenue Grows 21% YoY

Consolidated Results (Q1 FY27 vs Q1 FY26):

Revenue from Operations: ₹110.2 crore (vs ₹91.4 crore), representing 20.7% YoY growth
Gross Profit: ₹71.5 crore (vs ₹62.1 crore), 15.3% YoY growth
Gross Margin: 64.9% (vs 67.9%)
EBITDA: ₹26.0 crore (vs ₹24.7 crore), 5.2% YoY growth
EBITDA Margin: 23.6% (vs 27.0%)
Profit Before Tax: -₹1.3 crore (vs ₹3.0 crore)
Profit After Tax: -₹1.4 crore (vs ₹1.8 crore)
PAT Margin: -1.3% (vs 2.0%)
Cash PAT (PAT + Depreciation): ₹25.6 crore (vs ₹21.7 crore), 17.8% YoY growth

Standalone Results (Q1 FY27 vs Q1 FY26):

Revenue: ₹86.1 crore (vs ₹71.3 crore)
Gross Profit: ₹57.8 crore (vs ₹50.9 crore), 13.6% YoY growth
Gross Margin: 67.1% (vs 71.4%)
EBITDA: ₹24.2 crore (vs ₹22.2 crore), 8.7% YoY growth
EBITDA Margin: 28.1% (vs 31.2%)
Profit Before Tax: ₹0.9 crore (vs ₹4.8 crore), -80.7% YoY
Profit After Tax: ₹0.7 crore (vs ₹3.6 crore), -81.0% YoY
PAT Margin: 0.8% (vs 5.0%)
Cash PAT: ₹25.2 crore (vs ₹21.3 crore), 18.4% YoY growth

Revenue Breakdown:

Domestic Business: Delivered 17% YoY growth in Q1 FY27, supported by revival in demand across product categories and wide distribution network
Exports Business: Grew 29% YoY, rebounding strongly after impact of global geopolitical tensions in previous quarter
Nerbe Business: Delivered steady performance during the quarter

Mr. Aryan Sehgal, Promoter and Whole Time Director, commented:

Revenue growth driven by deeper customer penetration and improving underlying demand
Customer enquiries remain encouraging, supporting confidence in sustained demand momentum
Growth largely driven by existing portfolio with limited contribution from newer product categories
Margins impacted by: (1) Higher raw material prices due to supply chain disruptions from geopolitical challenges, (2) Change in product mix, (3) Expenses associated with new Amta and Panchla facilities
New facilities have partially commenced commercial operations with utilization expected to improve progressively over next two years
Amta facility has started with commercial supplies
Cell culture lines at Panchla facility expected to be commissioned towards end of Q2 FY27
Company positioned to accelerate growth through new customers, deeper client relationships, and scaled export business
Backed by over four decades of customer relationships and brand equity
Investing during down cycle to strengthen capacities and capabilities for sustainable growth over next 3-5 years

The company operates 7 manufacturing facilities in West Bengal:

| Burroshibtolla I | 530 | Leased | 4.5% |

| Burroshibtolla II | 1,022 | Leased | 5.5% |

| Kasba | 515 | Leased | 2.8% |

| Jangalpur | 15,142 | Owned | 47.9% |

| Dhulagarh | 4,047 | Leased | 22.9% |

| Panchla | 21,550 | Owned | 15.4% |

| Amta | 24,280 | Owned | 1.0% |

Key Manufacturing Highlights:

Vertically integrated manufacturing with in-house design & development
Automated manufacturing with robotics and technologies from overseas partners
Production process free from human touch for desired purity levels
Manufacturing in ISO 8 clean rooms
Quality Certifications: ISO 9001, 13485 & 14001
Amta facility: New fulfillment center with in-house sterilization and manufacturing capability; revenue commenced from Q4 FY26
Panchla facility: Expansion into new product categories and capacity expansion; revenue from cell culture categories expected from H2 FY27

Company Profile:

Leading Indian labware company with 40+ years of experience
Designs, develops, manufactures, and markets consumables, reusables, and benchtop equipment
Products used in research organizations, academia, pharmaceutical companies, CROs, diagnostic companies, and hospitals
2,000+ SKUs across 350 product segments
Pan-India distribution network with long-standing distributor relationships
Global reach with 45+ authorized distributors supplying to 40+ countries
Well-recognized brands: Maxipense, Spinwin, Cryochill

Competitive Advantages:

Growth Strategies: